$LFMD

LifeMD Reports Third Quarter 2025 Results

• Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.
• Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.
• Paid off all outstanding debt during the quarter.
• Subsequent to quarter end, fully divested our majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.
• Continued to diversify clinical platform with new launches in women’s health, men’s health and psychiatry.

$LFMD

❌ Earnings Miss

Adj. EPS: $(0.06) (vs. $(0.01) est)

YoY: ↓ 200.0% (from $0.06)

❌ Revenue Miss

Sales: $62.20M (vs. $66.34M est)

YoY: ↑ 22.8% (from $50.66M)

Added another 300 stock (for a total of 800) of $LFMD with high hopes and expectations. Focus to sell is in 1-2 years, when the company is expected to turn profitable and I am assuming the valuation will jump a lot. May hold for longer, since company may have a bright future ahead of them.

$LFMD earnings highlights for Q1 2025:

• Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70%
• Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period
• Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period
• GAAP net income of $0.6 million or $0.01 per diluted share, delivering first-ever quarter of positive GAAP EPS
• Raising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth

$LFMD

$LFMD

LifeMD said Thursday it expanded its insurance acceptance to include Medicare beneficiaries for qualifying virtual primary care, including weight management programs.

The company said over 21 million Medicare Part B beneficiaries in 26 states now have access to virtual care services.

LifeMD said it targets to expand access to medical services to over 60 million Medicare beneficiaries across 49 states by the end of Q2.

LifeMD shares were up more than 2% in recent trading.

$LFMD

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%

   ●  Adjusted EBITDA increased 78% to $9.0 million

   ●  Telehealth adjusted EBITDA increased 396% to $5.9 million

   ●  Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow

   ●  Exited 2024 with over $35 million in cash

   ●  Introduces 2025 guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million 

LifeMD Q4 Adj EPS $(0.02) Beats $(0.05) Estimate

Sales $64.25M Beat $57.38M Estimate

LifeMD Sees Q1 Revenue $61M-$63M Vs $59.447M Est.

FY25 Revenue $265M-$275M Vs $257.23M Est